Six months of hybrid closed loop in the real-world: An evaluation of children and young adults using the 670G system

被引:111
|
作者
Berget, Cari [1 ]
Messer, Laurel H. [1 ]
Vigers, Tim [2 ]
Frohnert, Brigitte I. [1 ]
Pyle, Laura [1 ,2 ]
Wadwa, R. Paul [1 ]
Driscoll, Kimberly A. [1 ,3 ]
Forlenza, Gregory P. [1 ]
机构
[1] Univ Colorado, Sch Med, Barbara Davis Ctr Childhood Diabet, Anschutz Campus, Aurora, CO 80045 USA
[2] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA
[3] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA
关键词
pediatrics; artificial pancreas; automated insulin delivery; continuous glucose monitor; INSULIN DELIVERY-SYSTEM; QUALITY-OF-LIFE; PROBLEM AREAS; TYPE-1; ADOLESCENTS;
D O I
10.1111/pedi.12962
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To describe glycemic and psychosocial outcomes in youth with type 1 diabetes using a hybrid closed loop (HCL) system. Subjects Youth with type 1 diabetes (2-25 years) starting the 670G HCL system for their diabetes care were enrolled in an observational study. Methods Prospective data collection occurred during routine clinical care and included glycemic variables (sensor time in range [70-180 mg/dL], HbA1c), and psychosocial variables (Hypoglycemia Fear Survey [HFS]; Problem Areas in Diabetes [PAID]). Mixed models were used to analyze change across time. Results Ninety-two youth (mean age 15.7 +/- 3.6 years, 50% female, HbA1c 8.8% +/- 1.8%) started HCL for their diabetes care. Youth used Auto Mode 65.5% +/- 3.0% of the time at month 1, which decreased to 51.2% +/- 3.4% at month 6 (P = .001). Sensor time in range increased from 50.7% +/- 1.8% at baseline to 56.9% +/- 2.1% at 6 months (P = .007). HbA1c decreased from 8.7% +/- 0.2% at baseline to 8.4% +/- 0.2% after 6 months of use (P <= .0001), with the greatest HbA1c decline in participants with high baseline HbA1c. Increased percent time in auto mode was associated with lower HbA1c (P = .02). Thirty percent of youth discontinued HCL in the first 6 months of use. There were no changes in the HFS or PAID scores across time. Conclusions HCL use is associated with improved glycemic control and no change in psychosocial outcomes in this clinical sample. The decline in HCL use across time suggests that youth experience barriers in sustaining use of HCL. Further research is needed to understand reasons for HCL discontinuation and determine intervention strategies.
引用
收藏
页码:310 / 318
页数:9
相关论文
共 50 条
  • [31] HYBRID CLOSED-LOOP CONTROL USING THE MEDTRONIC 670G AND ENLITE3 SYSTEM IN TYPE 1 DIABETES AT DIABETES CAMP
    Ly, T.
    Roy, A.
    Grosman, B.
    Shin, J.
    Campbell, A.
    Monirabbasi, S.
    Liang, B.
    Shanmugham, S.
    Clinton, P.
    Buckingham, B.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 : A20 - A20
  • [32] A comparative effectiveness analysis of real-world use of the MiniMed™640G and MiniMed™ 670G systems
    Shin, J.
    Huang, S.
    Chen, X.
    Nguyen, M. -H.
    Corder, T. L.
    Lee, S. W.
    Kaufman, F. R.
    DIABETOLOGIA, 2018, 61 : S396 - S397
  • [33] Glycemic Outcomes after Six Months of Real-World MiniMed 780G Advanced Hybrid Closed-Loop (AHCL) Therapy Use in Chile
    Castro, Matias
    Bonilla, Camila Nicole Carrasco
    Macedo, Joana C. Leon
    Gutierrez, Maria Fernanda
    Lopez, Zeudi C. Valera
    Daghero, Andrea
    DIABETES, 2022, 71
  • [34] TRANSLATING STANDARD CLINICAL PROTOCOL INTO TUNING PROCEDURES FOR HYBRID CLOSED LOOP SYSTEMS: 670G, CONTROL-IQ AND LOOP
    Kushner, T.
    Forlenza, G.
    Messer, L.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A79 - A79
  • [35] Glucose control during Ramadan fasting in a teenager with type 1 diabetes on MiniMed 670G hybrid closed-loop system
    Petrovski, Goran
    Al Khalaf, Fawziya
    Campbell, Judith
    Hussain, Khalid
    Fisher, Hannah
    Umer, Fareeda
    ACTA DIABETOLOGICA, 2020, 57 (01) : 105 - 107
  • [36] Overnight Insulin Delivery and Glucose in Children Using the MiniMed™ 670G System
    Roy, Anirban
    Grosman, Benyamin
    Parikh, Neha
    Wu, Di
    Lee, Scott W.
    Kaufman, Francine R.
    DIABETES, 2018, 67
  • [37] The MiniMed™ 670G Hybrid Closed-Loop (HCL) System and Patient-Reported Outcomes Concerning Quality of Life Measures
    Gopalakrishnan, Shweta
    Fogel, Catherine
    Mueckler, John
    DIABETES, 2018, 67
  • [38] Glucose control during Ramadan fasting in a teenager with type 1 diabetes on MiniMed 670G hybrid closed-loop system
    Goran Petrovski
    Fawziya Al Khalaf
    Judith Campbell
    Khalid Hussain
    Hannah Fisher
    Fareeda Umer
    Acta Diabetologica, 2020, 57 : 105 - 107
  • [39] Effect of Optimized Settings during Six Months of Real-World MiniMed 780G Advanced Hybrid Closed-Loop (AHCL) Therapy Use in Chile
    Castro, Matias
    Bonilla, Camila Nicole Carrasco
    Macedo, Joana C. Leon
    Gutierrez, Maria Fernanda
    Lopez, Zeudi C. Valera
    Daghero, Andrea
    DIABETES, 2022, 71
  • [40] Time-in-Target Glucose Range and the Glucose Management Indicator during Real-World MiniMed™ 670G System Use
    Gopalakrishnan, Shweta
    Cordero, Toni L.
    Sadeghzadeh, Mahta
    Stone, Michael
    Agrawal, Pratik
    DIABETES, 2019, 68